|
gptkbp:instanceOf
|
gptkb:drug
anticonvulsant
|
|
gptkbp:approvalYear
|
1999
|
|
gptkbp:approvedBy
|
gptkb:United_States
gptkb:FDA
|
|
gptkbp:ATCCode
|
N03AX14
|
|
gptkbp:availableOn
|
gptkb:tablet
intravenous solution
oral solution
|
|
gptkbp:bioavailability
|
near 100%
|
|
gptkbp:brand
|
gptkb:Keppra
gptkb:Elepsia_XR
gptkb:Spritam
|
|
gptkbp:CASNumber
|
102767-28-2
|
|
gptkbp:chemicalFormula
|
C8H14N2O2
|
|
gptkbp:contraindication
|
hypersensitivity to levetiracetam
|
|
gptkbp:developedBy
|
gptkb:UCB_Pharma
|
|
gptkbp:discoveredIn
|
1990s
|
|
gptkbp:drugClass
|
racetam
|
|
gptkbp:eliminationHalfLife
|
6-8 hours
|
|
gptkbp:excretion
|
renal
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
levetiracetam
|
|
gptkbp:interactsWith
|
none significant
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
binds to synaptic vesicle protein SV2A
|
|
gptkbp:MedlinePlusID
|
a699059
|
|
gptkbp:metabolism
|
minimal hepatic
|
|
gptkbp:molecularWeight
|
170.21 g/mol
|
|
gptkbp:patentExpired
|
2008 (US)
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:proteinBinding
|
<10%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1379
gptkb:DB01202
5284583
|
|
gptkbp:riskOfSuicidalThoughts
|
yes
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
dizziness
fatigue
headache
aggression
drowsiness
irritability
|
|
gptkbp:synonym
|
(S)-α-ethyl-2-oxo-1-pyrrolidine acetamide
|
|
gptkbp:UNII
|
S88TT14065
|
|
gptkbp:usedFor
|
epilepsy
myoclonic seizures
tonic-clonic seizures
partial-onset seizures
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:4-aminobutanoic_acid
|
|
gptkbp:bfsLayer
|
6
|